Informations sur le produit
- (17S-trans)-18-(2-Carboxyethyl)-12-ethenyl-7-ethyl-17,18-dihydro-3,8,13,17-tetramethyl-21H,23H-porphine-2,20-dicarboxylic acid cyclic 2,20-anhydride
- 3-[(10Z,14Z,20Z,22S,23S)-17-ethenyl-12-ethyl-13,18,22,27-tetramethyl-3,5-dioxo-4-oxa-8,24,25,26-tetraazahexacyclo[19.2.1.16,9.111,14.116,19.02,7]heptacosa-1(24),2(7),6(27),8,10,12,14,16,18,20-decaen-23-yl]propanoic acid (non-preferred name)
Purpurin 18 is a choroidal neovascularization inhibitor that binds to ABCG2, an efflux pump protein in the blood-brain barrier. This binding prevents efflux of the drug, which leads to inhibition of ABCG2-mediated transport of hydrophobic drugs and xenobiotics out of cells. Purpurin 18 has been shown to inhibit tumor growth in vivo by a mechanism that may involve inhibition of vascular endothelial growth factor (VEGF) production. Purpurin 18 also has anti-inflammatory properties and can be used for the treatment of alopecia areata. The anti-inflammatory effects are probably caused by inhibition of prostaglandin synthesis and induction of apoptosis in activated T cells. The uptake of purpurin 18 into cells is mediated by an acidic environment as well as its hydroxyl group, which provides it with a hydrophobic effect. Purpurin 18 also disrupts mitochondrial membrane potential, leading to cell death.
